Biogen
BIIB
988 hedge funds and large institutions have $37.1B invested in Biogen in 2019 Q3 according to their latest regulatory filings, with 78 funds opening new positions, 319 increasing their positions, 416 reducing their positions, and 94 closing their positions.
6% more funds holding in top 10
Funds holding in top 10: 16 → 17 (+1)
3.51% more ownership
Funds ownership: 83.33% → 86.84% (+3.5%)
1% less capital invested
Capital invested by funds: $37.6B → $37.1B (-$451M)
2% less funds holding
Funds holding: 1,010 → 988 (-22)
17% less first-time investments, than exits
New positions opened: 78 | Existing positions closed: 94
23% less call options, than puts
Call options by funds: $1.07B | Put options by funds: $1.38B
23% less repeat investments, than reductions
Existing positions increased: 319 | Existing positions reduced: 416
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$405M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$146M |
| 3 |
HM
HealthCor Management
New York
|
+$83.1M |
| 4 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$81.5M |
| 5 |
BS
Banco Santander
Madrid,
Spain
|
+$79.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$192M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$168M |
| 3 |
BlackRock
New York
|
-$134M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$124M |
| 5 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$103M |
BIIB Hedge Fund Activity: Q3 2019 in Review
988 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q3 2019, worth a combined $37.1B — down 1.2% from $37.6B a quarter earlier.
Sellers outnumbered buyers: 94 funds closed out of BIIB and 78 opened new positions — a net loss of 16 holders — while 416 trimmed existing stakes and 319 added.
The largest buyer was Renaissance Technologies, adding an estimated $405M. The largest seller was Capital World Investors, cutting an estimated $192M.
- 988 institutional investors held Biogen (BIIB) as of Q3 2019, down from 1,010 in Q2 2019.
- Funds reported $37.1B of Biogen stock for Q3 2019, down 1.2% quarter-over-quarter.
- 78 funds opened new Biogen positions in Q3 2019 and 94 closed out, a net change of -16 holders.
- The largest Biogen buyer in Q3 2019 was Renaissance Technologies, an estimated $405M added.
- The largest Biogen seller in Q3 2019 was Capital World Investors, an estimated $192M sold.
Based on aggregated 13F filings for Q3 2019.